Accès ouvert

Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease

Article scientifique 2025 Anglais

Résumé

BACKGROUND AND AIM: The Albumin Platelet Product (APP) has emerged as a promising non-invasive biomarker for fibrosis staging in chronic liver disease (CLD). This cross-sectional study aims to evaluate the effectiveness of APP compared to established non-invasive markers of fibrosis in an Egyptian cohort with HCV-related CLD. METHODS: 580 participants were assessed across different fibrosis stages (F0-F4) to analyze the relationship between APP and liver fibrosis. APP was compared with FIB-4 and APRI scores for diagnostic performance. RESULTS: The study included 580 patients with HCV-related CLD (mean age: 37.6 ± 9.66 years; 74.3% males). APP proved superiority in identifying liver cirrhosis (F4) at Cut-off values ≤ 0.59 with 81% sensitivity, 63.6% specificity (p < 0.001). APP showed a significant correlation with fibrosis stages, with an AUC of 0.920 (95% CI: 0.888-0.953) for distinguishing F4 from F0-F3 surpassing both FIB4 and APRI scores. However, FIB-4 proved superiority in distinguishing advanced fibrosis (F ≥ 3) with AUC of 0.899 (95% CI: 0.871-0.927) compared to APP with AUC of 0.87 (95% CI: 0.84-0.90), respectively. Multivariate analysis confirmed APP as an independent predictor of fibrosis (OR: 0.997, 95% CI: 0.995-0.998; p < 0.001). CONCLUSION: APP showed the highest performance in predicting cirrhosis, suggesting its potential as a simple, non-invasive marker for identifying patients with advanced liver disease. Its integration into clinical practice may enhance early detection and risk stratification in chronic HCV-related fibrosis. However, further multicenter, longitudinal studies are required to validate its efficacy across diverse populations and other liver disease etiologies.

Citer ce document

Elsabaawy, M., Eissa, M., Shaban, A., Naguib, M. (2025). Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease. https://doi.org/10.1038/s41598-025-07456-x

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Auteur(s)

Maha Elsabaawy Mohamed Eissa Ahmed Shaban Madiha Naguib

Statistiques

Consultations : 1

Téléchargements : 0